Goserelin Implant Suppliers & Bulk Manufacturers
Available Forms: Implant in pre-filled syringe applicator (subcutaneous)
Available Strengths: 3.6 mg (1-month), 10.8 mg (3-month)
Pack Sizes: Single applicator
Originator reference: Zoladex, Zoladex LA (brand names belong to their owners and are shown only to identify the originator medicine)
Category: Oncology Cancer Care
Goserelin implant (reference Zoladex) is a hormone therapy for prostate cancer, hormone-sensitive breast cancer and endometriosis. It is placed under the skin of the abdomen every month (3.6 mg) or every three months (10.8 mg). PharmaTradz connects hospital, tender and distributor buyers with GMP-certified manufacturers and licensed exporters, and checks the documents needed for the destination market.
Manufacture or export Goserelin Implant? List it or send an offer →
Product Description:
Goserelin is a synthetic version of gonadotropin-releasing hormone (GnRH). Given continuously, it first stimulates and then switches off the pituitary signals that drive the testes and ovaries. Testosterone in men and oestrogen in pre-menopausal women fall to very low levels, which slows the growth of hormone-dependent cancers and shrinks endometrial tissue.
It is used for advanced and locally advanced prostate cancer, for hormone-receptor-positive breast cancer in pre- and peri-menopausal women, and for endometriosis and some other gynaecological conditions. The small biodegradable implant comes inside a pre-filled applicator and is injected under the skin of the abdomen. The 3.6 mg implant lasts one month and the 10.8 mg implant three months.
Sourcing notes. Goserelin is off-patent, and generic implants are registered in a number of markets, although the applicator design makes it harder to produce than tablets. Hospital and oncology tenders usually specify the strength and shelf life. Leuprolide and triptorelin are also listed on PharmaTradz as alternative GnRH agonists.
Handling, dosing and buyer checklist
Storage and use. The implant comes ready to use in a single-use applicator and is stored at room temperature, so it does not need a cold chain. It is injected under the skin of the front of the abdomen by a nurse or doctor; the 3.6 mg implant is repeated every 28 days and the 10.8 mg implant every 12 weeks.
Clinical points. In prostate cancer, testosterone rises briefly in the first weeks before falling, so an anti-androgen is often given at the start to prevent a "flare". Long-term treatment lowers bone density, which doctors monitor. In women, menstrual periods stop during treatment.
What to ask a supplier. Strength and applicator type, registration status in the destination market (generic implants are registered in some markets only), comparative data against the reference product, remaining shelf life, and whether the product can be imported for tender or named-patient supply where it is not registered.
Goserelin Implant — third party manufacturing & bulk supply
Goserelin Implant is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Goserelin Implant is supplied as Implant in pre-filled syringe applicator (subcutaneous) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Goserelin Implant listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Goserelin Implant →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Prostate cancer, hormone-sensitive breast cancer in pre-menopausal women, and endometriosis.
3.6 mg (lasting one month) and 10.8 mg (lasting three months).
Zoladex. Brand names are shown for identification only.
Yes, in several markets. We confirm registration status for your destination before quoting.
Related Products
Pegaspargase Injection
Strength:
3,750 IU/5 mL (750 IU/mL)
Form: Solution or lyophilised powder vial (IM/IV)
Originator reference: Oncaspar
View DetailsStreptozocin for Injection
Strength:
1 g
Form: Lyophilised powder vial (IV)
Originator reference: Zanosar
View DetailsTasurgratinib Tablets
Strength:
35 mg
Form: Tablets
Originator reference: Tasfygo (Japan)
View DetailsGedatolisib for Injection
Strength:
180 mg
Form: Powder vial (IV infusion)
Originator reference: Revtorpyk
View DetailsTarlatamab-Dlle.
Strength:
1 mg, 10 mg
Form: Injection
Originator reference: Imdelltra (USA), Imdylltra (EU/UK)
View DetailsImlunestrant Tosylate
Strength:
200 mg
Form: Tablets
Originator reference: Inluriyo (USA)
View DetailsDecitabine + Cedazuridine
Strength:
35 mg + 100mg
Form: Tablets
Originator reference: Inqovi (USA/EU)
View DetailsFedratinib
Strength:
100mg, 200mg
Form: Capsules
Originator reference: Inrebic (USA/EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit